MNPR today
$71.73-$0.05 (-0.07%)close Nov 11, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourAscending Triangle
15 minStrong Bearish
5 minAscending Triangle
Daily trend turns up above $85.49
Key levels
Resistance$85.49
Resistance$75.31
Support$69.33
Support$64.95
Latest news & SEC filings
ProductMonopar Therapeutics Presents Baseline Data From Phase 3 FoCus Trial in Wilson Disease
EarningsMonopar Therapeutics to Report Q3 2026 Financial Results
SEC FilingMonopar Therapeutics filed an insider trading report (Form 4)
All MNPR news →About Monopar Therapeutics
Monopar Therapeutics is a clinical-stage biopharmaceutical company that develops proprietary treatments for cancer and other serious diseases. Its pipeline includes ALXN1840, licensed from AstraZeneca for Wilson disease, and MNPR-101, a radiopharmaceutical candidate being developed with NorthStar. The company relies on patents, trade secrets, and licensing agreements, and operates primarily in the United States.
Based on the company's 10-K filed Mar 27, 2026.
Nasdaq · Healthcare
Monopar Therapeutics (MNPR)
What Is the Price Target for MNPR?
SEPT Low Target
$105.00
SEPT Mid Target
$122.00
SEPT High Target
$145.00
Analyst Consensus
$122.00
Is MNPR a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for MNPR.
Start Free Trial →Is MNPR Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$122.00
12
Moat Score
NONE
4/9
Piotroski Score
107.4
Altman Z-Score
What Is Smart Money Doing with MNPR?
Insider Signal
SELLING
0 buys / 13 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Tsuchimoto Kim R | director | Buy | 856 | $26K | Nov 4, 2026 |
| Tsuchimoto Kim R | director | Buy | 2,035 | $28K | Nov 4, 2026 |
| Tsuchimoto Kim R | director | Sale | 1,295 | $92K | Nov 4, 2026 |
| Tsuchimoto Kim R | director | Sale | 996 | $71K | Nov 4, 2026 |
| Tsuchimoto Kim R | director | Sale | 600 | $43K | Nov 4, 2026 |
| Anderson Raymond | director | Buy | 1,402 | $42K | Nov 2, 2026 |
| Anderson Raymond | director | Buy | 1,740 | $52K | Nov 2, 2026 |
| Anderson Raymond | director | Sale | 840 | $56K | Nov 2, 2026 |
| Anderson Raymond | director | Sale | 600 | $40K | Nov 2, 2026 |
| Anderson Raymond | director | Sale | 200 | $14K | Nov 2, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →MNPR Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
N/A
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for MNPR
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for MNPR, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 19:45:18 | $72.33 | 1,100 | $$80K | MIDPOINT |
| 16:40:56 | $71.57 | 1,500 | $$107K | SELL |
| 15:01:19 | $71.17 | 1,100 | $$78K | SELL |
| 14:54:55 | $71.66 | 1,100 | $$79K | MIDPOINT |
| 19:30:02 | $70.73 | 1,300 | $$92K | MIDPOINT |
5 dark pool trades shown · $$436K preview volume
Real-time institutional flow, block trades, and net positioning
What Traders Are Saying About MNPR
1 postsSEPT Investing hosts an active community of 3,500+ traders sharing real-time analysis, trade setups, and market discussion for MNPR. Join verified traders discussing price action, dark pool alerts, options flow, and AI-powered market intelligence.
Smart Money Moves $RMBI — Cook Christopher D | Sale $23K $AEYE — HAWKINS JAMES B | Sale $38K $MNPR — Tsuchimoto Kim R | Sale $26K $MNPR — Tsuchimoto Kim R | Sale $28K $MNPR — Tsuchimoto Kim R | Sale ...
Join 3,500+ traders discussing MNPR in real-time
Trade ideas, setups, dark pool alerts, and AI-powered analysis
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Monopar Therapeutics (MNPR) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →MNPR — frequently asked questions
What is MNPR stock price today?
Monopar Therapeutics (MNPR) is at $71.73, down 0.07% (-$0.05) at the Nov 11, 2026 close.
Why is MNPR stock moving today?
Latest MNPR news — Nov 9, 2026: Monopar Therapeutics Presents Baseline Data From Phase 3 FoCus Trial in Wilson Disease · Nov 6, 2026: Monopar Therapeutics to Report Q3 2026 Financial Results
What is the MNPR price target?
The average analyst price target for MNPR is $122.00, ranging from $105 to $145, based on 6 analysts. Latest: Barclays maintains on Sep 11, 2026.
What do analysts rate MNPR?
Analyst ratings for MNPR: 0 Buy, 7 Hold, 1 Sell — consensus Hold.
Did MNPR beat earnings?
MNPR last reported on Aug 12, 2026: EPS -$0.62 vs -$0.64 expected — a beat of 3.7%.
Does MNPR pay a dividend?
MNPR does not currently pay a dividend.
What are MNPR support and resistance levels?
Support: $69.33, $64.95, $58.01. Resistance: $75.31, $85.49, $97.71.
What are insiders doing with MNPR?
Insider activity: SELLING, 0 buys and 13 sells in the last 90 days.
What is the latest news on MNPR?
Nov 9, 2026: Monopar Therapeutics Presents Baseline Data From Phase 3 FoCus Trial in Wilson Disease · Nov 6, 2026: Monopar Therapeutics to Report Q3 2026 Financial Results · Nov 4, 2026: Monopar Therapeutics filed an insider trading report (Form 4)